285 related articles for article (PubMed ID: 26882318)
1. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.
LeWitt PA; Poewe W; Elmer LW; Asgharnejad M; Boroojerdi B; Grieger F; Bauer L
Clin Neuropharmacol; 2016; 39(2):88-93. PubMed ID: 26882318
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B;
Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486
[TBL] [Abstract][Full Text] [Related]
4. Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Zhang ZX; Liu CF; Tao EX; Shao M; Liu YM; Wang J; Asgharnejad M; Xue HB; Surmann E; Bauer L
Parkinsonism Relat Disord; 2017 Nov; 44():6-12. PubMed ID: 28827011
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
Nicholas AP; Borgohain R; Chaná P; Surmann E; Thompson EL; Bauer L; Whitesides J; Elmer LW;
J Parkinsons Dis; 2014; 4(3):361-73. PubMed ID: 24643203
[TBL] [Abstract][Full Text] [Related]
6. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
[TBL] [Abstract][Full Text] [Related]
7. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Sanford M; Scott LJ
CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
[TBL] [Abstract][Full Text] [Related]
8. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
Nomoto M; Iwaki H; Kondo H; Sakurai M
J Neurol; 2018 Feb; 265(2):253-265. PubMed ID: 29164312
[TBL] [Abstract][Full Text] [Related]
10. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
[TBL] [Abstract][Full Text] [Related]
11. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K; Lyons KE
Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
[TBL] [Abstract][Full Text] [Related]
12. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
Mizuno Y; Nomoto M; Hasegawa K; Hattori N; Kondo T; Murata M; Takeuchi M; Takahashi M; Tomida T;
Parkinsonism Relat Disord; 2014 Dec; 20(12):1388-93. PubMed ID: 25455692
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
[TBL] [Abstract][Full Text] [Related]
14. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
15. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).
Trenkwalder C; Kies B; Rudzinska M; Fine J; Nikl J; Honczarenko K; Dioszeghy P; Hill D; Anderson T; Myllyla V; Kassubek J; Steiger M; Zucconi M; Tolosa E; Poewe W; Surmann E; Whitesides J; Boroojerdi B; Chaudhuri KR;
Mov Disord; 2011 Jan; 26(1):90-9. PubMed ID: 21322021
[TBL] [Abstract][Full Text] [Related]
16. Rotigotine transdermal system for the treatment of Parkinson's disease.
Pham DQ; Nogid A
Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
[TBL] [Abstract][Full Text] [Related]
17. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease.
Woitalla D; Dunac A; Safavi A; Ceravolo MG; Gomez Esteban JC; Pavese N; Asgharnejad M; Joeres L; Schuller JC; Chaudhuri KR
Expert Opin Pharmacother; 2018 Jun; 19(9):937-945. PubMed ID: 29916262
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
Giladi N; Ghys L; Surmann E; Boroojerdi B; Jankovic J
Parkinsonism Relat Disord; 2014 Dec; 20(12):1345-51. PubMed ID: 25444083
[TBL] [Abstract][Full Text] [Related]
19. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease.
Hirano M; Isono C; Fukuda K; Ueno S; Nakamura Y; Kusunoki S
J Neurol Sci; 2019 Sep; 404():5-10. PubMed ID: 31323520
[TBL] [Abstract][Full Text] [Related]
20. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
